Background: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children
with Acute Lymphoblastic Leukaemia (ALL) was investigated, examining effects of age, gender, risk
stratified treatment regimen (A,B,C) and therapy intensity (1 vs 2 ‘delayed intensifications’: DI).
Method:
In a multi-centre prospective study, parents reported their child’s generic and disease specific
HRQoL and their own care-giving burden at five time-points. From 1428 eligible patients, 874
parents completed questionnaires at least once during treatment.
Results:
At each time-point, generic HRQoL was significantly lower than equivalent norm scores for healthy
children. HRQoL decreased significantly at the start of treatment, before recovering gradually (but
remained below pre-treatment levels). Parents reported that older children worried more about side effects and their appearance but showed less procedural anxiety than younger children. Concern for appearance was greater among girls than boys. Compared to regimen B (i.e.additional doxorubicin
during induction and additional cyclophosphamide and cytarabine during consolidation
chemotherapy), patients receiving regimen A had fewer problems with pain and nausea. There were
no statistically significant differences in HRQoL by number of DI blocks received.
Interpretation: HRQoL is compromised at all stages of treatment, and is partly dependent on age.
The findings increase understanding of the impact of therapy on children’s HRQoL and parental caregiving burden, and will contribute to the design of future trials.
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)